There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Clovis Oncology Inc. (CLVS) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by +$0.01, or +0.86%, to $1.17. Volume reached 23,453 shares, with price reaching a high of $1.21 and a low of $1.18. Recently, Yahoo Finance discussed the stock, revealing that Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement.
As a NASDAQ listed company, CLVS falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $1.18 and fluctuated between $1.2200 as its day high and $1.1250 as its day low. The current market capitalization of Clovis Oncology Inc. is $185.33M. A total of 2.46 million shares were traded on the day, compared to an average of 9.24M shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, CLVS has seen 12 BUY and 12 SELL insider trades, representing the acquisition of 40,819 and the disposition of 19,409 shares. Over the last 12 months, there were 72 BUYs and 72 SELLs from insiders. Insiders purchased 287,138 shares during that period but sold 142,647.
In the most recent transaction, MUEHL DANIEL W sold 2,234 shares of CLVS for 1.20 per share on Sep 02. After the transaction, the now owns 99,161 company shares. In a previous transaction on Sep 02, IVERS-READ GILLIAN C sold 2,234 shares at 1.20 per share. CLVS shares that owns now total 288,919.
Among the insiders who sold shares, Harding Thomas C. disposed of 172 shares on Sep 02 at a per-share price of $1.20. This resulted in the holding 3,674 shares of CLVS after the transaction. In another insider transaction, Harding Thomas C. sold 1,444 shares at $1.20 per share on Sep 02. Company shares held by the now total 17,816.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for CLVS in the last 3 months, the mean price target is $2.00 with high estimates of $2.00 and low estimates of $2.00. In terms of 52-week highs and lows, CLVS has a high of $4.91 and a low of $0.58.
As of this writing, CLVS has an earnings estimate of $-0.41 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of $-0.38 per share and a lower estimate of $-0.43. The company reported an EPS of $-0.43 in the last quarter, which was -2.38% lower than expectations of $-0.42.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 3 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CLVS is Buy with a score of 2.67. A total of 0 analysts rated the stock as Buy while 0 rated it as Overweight while 2 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 0 thought it should be Sold.